No abstract

BackgroundPatients with cardiogenic shock may require hemodynamic stabilization with short‐term mechanical circulatory support devices (ST‐MCS) such as extracorporeal membrane oxygenation (ECMO) and centrifugal pump (CP) as bridge to transplantion (BTT). This study aimed to describe ECMO and CP during BTT and after heart transplant.MethodsA cohort of patients on ECMO or CP as BTT between April 2006 and April 2018 in a single hospital.ResultsThirty‐seven consecutive patients with ECMO (n = 14) or CP (n = 23) were included. Acute kidney injury was more prevalent during CP (28.6% vs 69.6%, P = .02). There were no differences in stroke, thrombosis, sepsis, or vasoplegia. Bleeding (0% vs 56.5%, P = .0003) and reoperation (0% vs 47.8%, P = .002) were more frequent in CP group as well as mortality (0 vs 7 [30.4%], P = .03). The remaining 30 patients (81.1%) underwent heart transplantation, without differences in primary graft dysfunction, vasoplegia, reoperation for bleeding, or hospital stay. Mortality was 23.3% at 30 days, similar in both groups, with no further deaths at median follow‐up of 44.2 months.ConclusionsIn patients with cardiogenic shock, ST‐MCS with ECMO or CP as BTT are a lifesaving approach allowing successful transplantation in the majority of cases, with good short‐ and long‐term survival.

Hemoglobin A1c (HbA1c) level represents an established tool to monitor glycemic control in diabetic patients, but the previous commonly used tests of HbA1c in patients with end-stage renal disease (ESRD) may not be reliable because of the presence of anemia, assay interference from uremia, and decreased red blood cell (RBC) life span. HbA1c level measured by turbidimetric immunoassay method is not affected by the above factors. We enrolled 40 non-diabetic ESRD patients receiving hemodialysis and 55 non-diabetic patients without ESRD for this study. HbA1c was analyzed by turbidimetric immunoassays with Synchron CX system. We found that the average HbA1c level in non-diabetic ESRD patients receiving hemodialysis was 5.99% and in the control group was 5.45% (p<0.05). There was no significant difference in fasting glucose levels and Hct % between the two groups (p>0.05). Our limited data indicate that HbA1c levels are elevated in nondiabetic ESRD patients receiving hemodialysis. We propose that the elevated HbA1c level may be due to the repetitive exposure of patients' RBCs to the high glucose level in dialysate (200 mg/dl) or may reflect true glucose intolerance in non-diabetic patients with ESRD.

Background Supraventricular arrhythmias (SVAs), commonly managed with radiofrequency ablation (RFA), may occur after orthotopic heart transplantation (OHT). Methods We retrospectively assessed 514 consecutive patients (pts.) undergoing OHT between January 1990 and July 2016 in a single‐center. Patients with SVAs managed with RFA were included. Mechanisms of genesis of SVAs, association with surgical techniques and outcomes, were analyzed. Results Of 514 pts undergoing OHT, 53% (272 pts.) were managed with bicaval (BC) technique and 47% (242 pts.) with biatrial (BA) technique. Mean follow‐up 10 ± 8.4 years. Nine pts. (1.7%) developed SVA requiring RFA. The BC technique was performed in 4 pts., 3 pts. presented cavotricuspid isthmus‐dependent atrial flutter (CTI AFL), and 1 pt. double loop AFL. Five pts. were managed with BA technique, 4 pts. presented CTI AFL, and 1 pt. atrial tachycardia (AT). Mean time between OHT and SVA occurrence was 6.6 ± 5.5 years. The procedure was successful in 89% (8 pts.). Arrhythmia recurrence was seen in 3 pts (37%), all with BA technique. Conclusion Supraventricular arrhythmias in heart transplantation may be associated with the surgical scar. Identifying the mechanism is vital to choose the appropriate treatment with radiofrequency ablation.

No abstract